Irvine, Calif.
Went public 8/22/2000 at $10.50 per share
Filing Range: 3 mil. shares @ $13 to $15
Shares Outstanding: 15.9 mil. shares
Underwriters: CIBC World Markets/Prudential Vector Healthcare/Thomas Weisel Partners LLC
Company Counsel: Wilson Sonsini Goodrich & Rosati
Manager Counsel: Skadden, Arps, Slate, Meagher & Flom
Auditor: Ernst & Young LLP
The Company:
Develops contact lens to reshape the cornea and restore visual acuity without surgery. The company is currently conducting domestic and international clinical trials on Vitrase (a drug designed to rapidly clear vitreous hemorrhage) and on Corneaplasty (a non-surgical system to correct refractive vision errors.)
Venture Backers:
Sanderling Ventures
Invesco Private Capital
Domain Associates LLC
Financing Rounds:
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 08/16/1995 1 Later Stage 217.0
2 10/18/1995 1 Early Stage1 742.0
3 06/30/1997 3 Expansion 15000.0
4 09/28/1998 4 Later Stage 1000.0
5 11/17/1998 4 Expansion 5999.0
6 03/14/1999 4 Expansion 3000.0
Financials:
(Data in $ millions)
Y/E
12/31/99
Total Revenues: $0.0
Net Income: -14.3